MedPath

A multicenter randomized controlled trial of Qingre Liangxue therapy for psoriasis blood-heat syndrome

Not Applicable
Recruiting
Conditions
psoriasis
Registration Number
ITMCTR1900002639
Lead Sponsor
Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Western diagnostic criteria and diagnostic criteria for TCM syndromes that meet psoriasis;
2. Skin lesions involve <=10% BSA (the lesions are mainly located in the trunk and / or limbs, palm / sole, face / scalp, vulva area is not included);
3. Age between 18 and 65 years old;
4. Those who voluntarily participate in the study and sign the informed consent form.

Exclusion Criteria

1. Erythrodermic, arthritic, pustular psoriasis patients;
2. There are other active skin diseases that may affect the condition assessment;
3. Systematic treatment of research drugs, biological agents and immunosuppressive agents within 1 month;
4. Within 2 weeks, he received treatment with topical glucocorticoids, phototherapy, etc.;
5. During severe, uncontrollable local or systemic acute or chronic infections;
7. Patients with severe systemic diseases; or clinical test indicators in one of the following conditions: alanine aminotransferase or aspartate aminotransferase increased by >1.5 times the upper limit of normal; creatinine increased by 1.5 times the upper limit of normal; main indicators of blood routine ( Any one of the white blood cell count, red blood cell count, hemoglobin amount, and platelet count) is below the lower limit of normal; or other laboratory abnormalities are judged by the investigator to be unsuitable for participation in the trial;
8. Patients with a history of malignant tumors and primary or secondary immunodeficiency and hypersensitivity patients;
9. Those who have participated in other drug clinical trials within 3 months;
10. Such surgery will be required during major surgery or study within 8 weeks;
11. For women of childbearing age who have fertility, no effective contraceptive measures have been taken from the screening period until the end of the last dose;
12. Pregnant or lactating women;
13. Those who have a history of alcohol abuse, drug abuse or drug abuse;
14. Those with a history of serious mental illness or family history;
15. The investigator considered it inappropriate to participate in the study.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PASI;
Secondary Outcome Measures
NameTimeMethod
PGA;VAS;BSA;DLQI;recurrence rate;PRQoL;TCM symptom score;
© Copyright 2025. All Rights Reserved by MedPath